Heart failure redefined with new classifications, staging
March 8, 2021
Heart failure terminology gets a landmark reno, with a new universal definition, revised stages of development and progression, and updated LVEF classifications.
More from DAPA-HF: Dapagliflozin quickly reduces heart failure events
February 22, 2021
Secondary analysis of DAPA-HF showed dapagliflozin significantly cut CV deaths or worsening heart failure within 28 days on treatment.
FDA expands sacubitril/valsartan indication to embrace some HFpEF
February 17, 2021
The newly approved labeling for sacubitril/valsartan (Entresto) is simply for “chronic heart failure” but almost teasingly adds, “the benefits are most clearly evident” at below-normal LVEF.
More Americans hospitalized, readmitted for heart failure
February 16, 2021
“We should be emphasizing the things we know work to reduce heart failure hospitalization, which is, number one, prevention.”
Cardiac activity not uncommon after lifesaving measures stop
February 5, 2021
ECG and blood pressure monitoring identified resumption of cardiac activity in 14% of patients, all occurring in the 5 minutes after pulselessness.
Newer iPhones disable implanted defibrillators
February 1, 2021
Some newer smartphones are equipped with magnets sufficiently powerful to disable an implanted cardiac defibrillator.
Neprilysin, corin singled out for potential to guide heart failure therapy
January 28, 2021
Circulating neprilysin and corin concentrations, which correlate with outcomes, could possibly be assessed to guide heart failure therapy.
Myocarditis by CMR may be rare after COVID-19 in elite athletes
January 27, 2021
Some supposed ‘myocarditis’ detected by MRI after COVID-19 in university varsity competitors might be normal heart muscle – normal for athletes, that is, propose researchers.
Biomarker HF risk score envisioned as SGLT2 inhibitor lodestar in diabetes
January 19, 2021
Together, four “easily measured” biomarkers predicted 5-year heart failure risk in patients with diabetes or prediabetes, potentially identifying best candidates for SGLT2 inhibitor therapy, some say.
Updated ACC decision pathway embraces new heart failure treatment strategies
January 11, 2021
The ACC’s updated decision pathway aims to close the substantial gap between current practice and unmet opportunities for inhibiting HFrEF progression.